Additionally, patients undergoing PARP inhibitor therapy should be closely monitored for bleeding symptoms, such as mucosal and skin bleeding or visceral hemorrhage, which may serve as early warning signs of thrombocytopenia. This evidence concerns the gene PARP1 and Thrombocytopenia.